FDA Awards $1.1M Contract to CUBRC and EpiVax for Validation of New Immunoinformatic Tool for Prospective Immunogenicity Assessment of Peptide Drugs and Their Impurities

AsiaNet 86224

PROVIDENCE, Rhode Island, Oct. 22, 2020 /PRNewswire=KYODO JBN/ --

EpiVax, Inc. ("EpiVax") and CUBRC, Inc. ("CUBRC") announced today that they

have been awarded a two-year, $1.1 million contract from the Office of Generic

Drugs (OGD) in the Center of Drug Evaluation and Research (CDER) of the Food

and Drug Administration (FDA) in response to a Broad Agency Announcement (BAA),

FDA BAA-20-00123.

Logo - https://mma.prnewswire.com/media/542055/EpiVax_Logo.jpg

This program continues research performed during a previous two-year

collaboration between EpiVax and CUBRC. Under the previous FDA contract, EpiVax

demonstrated the value of in silico tools and in vitro validation methods for

the evaluation of generic peptide drugs and their impurities. EpiVax analyzed

the immunogenic risk of two generic peptide drugs, applying the concepts

outlined in FDA draft guidance, ANDAs for Certain Highly Purified Synthetic

Peptide Drug Products That Refer to Listed Drugs of rDNA Origin, published in

2017.

Since initiating the program, EpiVax has produced the What-if Machine (WhIM) –

an advanced immunoinformatics tool that performs iterative modifications to

synthetic peptide drugs entirely in silico, generating a comprehensive list of

all potential impurities that may occur due to deletions, insertions,

duplications or side chain modifications at any residue of the active

pharmaceutical ingredient (API). EpiVax uses existing algorithms to rank the

impurities produced by the WhIM for their immunogenic potential in global

patient populations. This output will enable one to identify high-, moderate-,

and low-risk impurities prospectively. The new contract will provide proof of

concept for the WhIM, again using two case studies as validation. EpiVax will

continue to work with Katie Edwards, PhD (CUBRC), Prime Technical Program Lead,

to achieve the goals set out in the contract.

Annie De Groot, MD (CEO/CSO, EpiVax) stated, "The WhIM has significant

potential to contribute to prospective identification of high-risk impurities,

allowing for generic peptide drug products to be de-risked early in the

development process."

About the Draft FDA Guidance on Generic Peptide ANDAs

The draft guidance issued by the Office of Generic Drugs highlighting the use

of in silico analysis in accelerated new drug applications for generic peptide

drugs can be found here  (UCM578365) (

https://c212.net/c/link/?t=0&l=en&o=2957016-1&h=2727640864&u=https%3A%2F%2Fwww.fda.gov%2Fdownloads%2FDrugs%2FGuidanceComplianceRegulatoryInformation%2FGuidances%2FUCM578365.pdf&a=(UCM578365)

).

About EpiVax

EpiVax is a biotechnology company leading in the fields of immunogenicity risk

assessment of biologic products and computational vaccinology with expertise in

T cell epitope prediction, immune modulation, and rapid vaccine design. Visit

www.epivax.com for more information.

About CUBRC

CUBRC is an independent not-for-profit scientific corporation that executes

Research, Development, Testing and Systems Integration programs in Medical

Sciences, Chemical and Biological Defense, Data Science and Information Fusion,

Command and Control, and Hypersonics.  Visit www.cubrc.org for more

information.

FDA Funding Statement

The FDA sponsors the project referenced in this press release. The content of

the information does not necessarily reflect the position or the policy of the

federal government, and no official endorsement should be inferred. The entire

project (~$1.1M) will be financed with federal money.

Press Contact:  

Katie Porter, Business Development Manager, EpiVax  

E: KPorter@epivax.com

SOURCE: EpiVax Inc.